MXPA03009720A - USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. - Google Patents

USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.

Info

Publication number
MXPA03009720A
MXPA03009720A MXPA03009720A MXPA03009720A MXPA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
against benign
Prior art date
Application number
MXPA03009720A
Other languages
English (en)
Inventor
Anthony P D W Ford
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03009720A publication Critical patent/MXPA03009720A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03009720A 2001-04-23 2002-02-02 USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. MXPA03009720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23
PCT/EP2002/001085 WO2002085458A2 (en) 2001-04-23 2002-02-02 Use of nk-1 receptor antagonists against benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
MXPA03009720A true MXPA03009720A (es) 2004-01-29

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009720A MXPA03009720A (es) 2001-04-23 2002-02-02 USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.

Country Status (17)

Country Link
US (1) US20030004157A1 (es)
EP (1) EP1385577B1 (es)
JP (1) JP4146730B2 (es)
KR (1) KR100599134B1 (es)
CN (1) CN100398106C (es)
AR (1) AR035935A1 (es)
AT (1) ATE323531T1 (es)
AU (1) AU2002250876B2 (es)
BR (1) BR0209151A (es)
CA (1) CA2444395C (es)
DE (1) DE60210760T2 (es)
DK (1) DK1385577T3 (es)
ES (1) ES2261657T3 (es)
MX (1) MXPA03009720A (es)
PT (1) PT1385577E (es)
WO (1) WO2002085458A2 (es)
ZA (1) ZA200308110B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
NZ541243A (en) * 2003-01-31 2008-04-30 Hoffmann La Roche New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
JP4490421B2 (ja) * 2003-07-03 2010-06-23 エフ.ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルnk1/nk3アンタゴニスト
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
JP4580426B2 (ja) 2004-07-06 2010-11-10 エフ.ホフマン−ラ ロシュ アーゲー Nk−1受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
EP1855655A2 (en) 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Tablets with improved drug substance dispersibility
SI2395002T1 (sl) 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Cftrのモジュレーター
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
PL2639223T3 (pl) 2007-12-07 2017-09-29 Vertex Pharmaceuticals Incorporated Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2010106988A1 (ja) 2009-03-17 2010-09-23 第一三共株式会社 アミド誘導体
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
EP2493299A4 (en) * 2009-10-29 2013-04-17 Merck Sharp & Dohme TERTIARY AMIDOREXIN RECEPTOR ANTAGONISTS
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与
EP3067349B1 (en) 2013-11-08 2018-02-28 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
EP3746077A4 (en) * 2018-02-02 2021-10-27 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) PARENTERAL FORMULATIONS AND USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
CN1272842A (zh) * 1997-08-06 2000-11-08 伊莱利利公司 作为速激肽受体拮抗剂的2-酰氨基丙胺类化合物
IL134155A0 (en) * 1997-08-06 2001-04-30 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
WO2002006236A1 (en) * 2000-07-14 2002-01-24 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
BR0209151A (pt) 2004-07-13
DE60210760D1 (de) 2006-05-24
CN1503684A (zh) 2004-06-09
WO2002085458A3 (en) 2003-10-30
CA2444395A1 (en) 2002-10-31
PT1385577E (pt) 2006-08-31
ES2261657T3 (es) 2006-11-16
AU2002250876B2 (en) 2005-03-03
EP1385577A2 (en) 2004-02-04
CN100398106C (zh) 2008-07-02
KR100599134B1 (ko) 2006-07-12
AR035935A1 (es) 2004-07-28
WO2002085458A2 (en) 2002-10-31
KR20040007503A (ko) 2004-01-24
EP1385577B1 (en) 2006-04-19
DE60210760T2 (de) 2006-11-23
ATE323531T1 (de) 2006-05-15
US20030004157A1 (en) 2003-01-02
CA2444395C (en) 2010-12-21
JP4146730B2 (ja) 2008-09-10
DK1385577T3 (da) 2006-08-21
JP2004529931A (ja) 2004-09-30
ZA200308110B (en) 2005-03-30

Similar Documents

Publication Publication Date Title
MXPA03009720A (es) USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
MXPA03006121A (es) Terapia de combinacion usando inhibidores del receptor tirosin-cinasa e inhibidores de la angiogenesis.
ZA200401214B (en) Synthesis of poly-alpha olefin and use thereof.
ITMI20002076A0 (it) Procedimento ed apparecchiatura per il controllo della miscelazione di bevande.
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
MXPA03000738A (es) Antagonistas de grelina.
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
IL158701A0 (en) Novel use of nk3 receptor antagonist
EP1359915A4 (en) UROTENSIN-II RECEPTOR ANTAGONISTS
AU8177801A (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
MXPA03003892A (es) Antagonistas del receptor bombesin.
ZA991315B (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
ZA200108038B (en) Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
WO2002062323A3 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
MXPA03004414A (es) Natagonistas del receptor bombesin.
ZA200403530B (en) Chemokine receptor antagonists and methods of use thereof.
HK1031872A1 (en) Phtalimido arylpiperazines as alpha 1a receptor antagonists useful in the treatment of benign prostatic hyperplasia.
EP1372639A4 (en) TREATMENT AGENT FOR BLADDER IRRITATION SYMPTOMS ACCOMPANIED WITH BENIGN PROSTATIC HYPERPLASIA
AU2001268442A1 (en) Identification of cdnas associated with benign prostatic hyperplasia
ZA200401146B (en) Agonists and antagonists of 5HT3-like receptor of invertebrates as pesticides.
DK1056720T3 (da) Phtalimido-arylpiperaziner som alfa-1A-receptorantagonister, der er nyttige til behandling af godartet prostatahyperplasi
MXPA03004249A (es) Nuevos usos de combinaciones selectivas antagonistas del receptor de dopamina d2 y agonistas del receptor de 5-ht1a.
AU2002348270A8 (en) Fire hydrant lock
GB2382281B (en) Authentication of network users

Legal Events

Date Code Title Description
FG Grant or registration